Please provide your email address to receive an email when new articles are posted on . A subcutaneous implantable cardioverter defibrillator was noninferior to a transvenous ICD regarding major ...

Please provide your email address to receive an email when new articles are posted on . In a new study, patients reimplanted with a subcutaneous implantable cardioverter defibrillator after the ...

In a typical population of patients requiring implantable cardioverter-defibrillator (ICD) therapy without pacing, mostly for the primary prevention of sudden cardiac death, a subcutaneous ICD (S-ICD; ...

Last year the FDA approved Boston Scientific's subcutaneous ICD, the first ICD that can defibrillate the heart without using leads threaded to the heart through the blood vessels. Those leads are the ...

The FDA today approved the Subcutaneous Implantable Defibrillator (S-ICD) system from Cameron Health. The device is the first ICD that does not require a lead that connects directly to the heart and ...

SAN FRANCISCO, CA—The subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific) prevents most of the major lead-related complications seen with a transvenous system, the ATLAS ...

Transvenous leads are the most common source of complications associated with the use of implantable cardioverter-defibrillators (ICDs). A preliminary experience with an entirely subcutaneous ICD ...

May 18, 2009 (Boston, Massachusetts) — Early results from a small, randomized clinical trial testing an implantable converter defibrillator (ICD) featuring a totally subcutaneous lead system (Cameron ...

Boston Scientific's Emblem S-ICD, the next generation subcutaneous ICD product, is a novel technology that removes what many believe is the weakest link in implantable cardioverter defibrillators - ...

NICE, FRANCE – A longer-term assessment of a new subcutaneous implantable cardioverter defibrillator (ICD) (Boston Scientific) shows that just over 90% of patients are free from complications at two ...

Implantable cardioverter-defibrillators (ICDs) reduce mortality in patients with increased risk of sudden cardiac death, but use of these devices has been limited by complications with the ...

This week, a nice article in the Boston Globe appeared on Boston Scientific’s subcutaneous implantable cardiac defibrillator (S-ICD) that recently received FDA approval. It was a fairly balanced ...